The Claim
In adults with atherosclerosis or diabetes and LDL cholesterol ≥90 mg/dL but no prior heart attack or stroke, evolocumab does not increase the incidence of serious adverse events compared to placebo over a median follow-up of 4.6 years.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with atherosclerosis or diabetes and high LDL cholesterol but no prior heart attack or stroke, taking evolocumab does not lead to more serious adverse events than taking a placebo over 4.6 years.
See the scientific wording
In adults with atherosclerosis or diabetes and LDL cholesterol ≥90 mg/dL but no prior heart attack or stroke, evolocumab does not increase the incidence of serious adverse events compared to placebo over a median follow-up of 4.6 years, indicating a favorable safety profile in this population.
A protein that normally removes LDL receptors from the liver is blocked, so more receptors stay on the liver surface to pull LDL cholesterol out of the blood. This lowers cholesterol levels without causing harmful side effects in people with high cholesterol and artery disease or diabetes.
What the research says
1 studyStudy: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.
This study gave people with high cholesterol and artery or diabetes issues evolocumab shots every two weeks for almost five years and found they didn’t have more serious side effects than those who got a fake shot. So, the drug is safe for them.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.